lidorestat

Lidorestat is a small molecule drug that acts as a highly potent and selective inhibitor of aldose reductase (AKR1B1), the key enzyme in the polyol pathway responsible for converting glucose to sorbitol. By inhibiting aldose reductase, lidorestat reduces the accumulation of sorbitol in insulin-insensitive tissues, which is implicated in the development of diabetic complications such as neuropathy, retinopathy, nephropathy, and cataracts. Lidorestat was developed primarily for the treatment of diabetic complications and has demonstrated good oral bioavailability and efficacy in preclinical models. The drug reached phase 2 clinical trials but its development status is now discontinued[1][3][5][6][7].

Other names

lindolrestatlindorestatLidorestat anhydrous